Table 1 CAR T cell therapy in lymphoma

Costimulation domain

CD-28

4-1BB

4-1BB

Vector

Retrovirus

Lentivirus

Lentivirus

Conditioning regimen

Fludarabine, cyclophosphamide

Fludarabine, cyclophosphamide, or bendamustine

Fludarabine, cyclophosphamide

Pivotal trial

ZUMA-1 (N = 108)

JULIET (N = 111)

TRANSCEND-NHL-001 (N = 102)

Histology

DLBCL, tFL, PMBCL

DLBCL, tFL

DLBCL,PMBCL, FL, tFL

CAR T cell dosage

2 × 10⁶ cells/kg

3 × 10⁸ cells/kg

1 × 10⁸ cells/kg

ORR

83%

52%

75%

CR

58%

40%

55%

Median DOR (months)

11.1 (95% CI, 4.2—NE)

NR (95% CI, 10—NR)

NA

Overall survival

24-month survival, 50.5% (95% CI 40.2–59.7)

11.7 months (95% CI, 6.6—NE)

NA

Any grade CRS/NT

93%/64 %

58%/21%

37%/25 %

Grade ≥ 3 CRS

13%

22%

1%

Grade ≥ 3 NT

28%

12%

15%

Tocilizumab/steroid usage

43%/27%

15%/10%

17%/21%

Grade 5 AEs

4%

None

None

Reference

[11, 13]

[9, 14]

[12, 15]